Developer docs
API playgroundTry for free, no card

Search company profiles

Celera

Full company profile

uuid0007xpn

Namestring
Celera
Legal namestring
Celera Genomics
Websiteurl
celera.com
Company typeenum
Private
Founded yearint
1998
Descriptiontext

Celera, legally known as Celera Genomics, was a private biotechnology company founded in 1998 by J. Craig Venter and headquartered in Rockville, Maryland. The company was established to compete with the publicly funded Human Genome Project by employing a whole-genome shotgun sequencing approach — a method that randomly fragments an entire genome into small pieces, sequences them in parallel, and reassembles them computationally. Celera successfully assembled the first human genome draft sequence and announced the result at the White House in 2000 alongside the NIH-led public consortium, validating the private-sector approach to large-scale genomics.

The company's core business centered on DNA sequencing services, genomic data generation, and synthetic biology applications, primarily serving research institutions and biomedical scientists who required faster, more cost-effective genome sequencing than the public mapping-based approach. Its horizontal segmentation strategy targeted scientific researchers needing genomic sequencing for their research programs. Beyond sequencing, the firm expanded through acquisitions of Axys Pharmaceuticals in June 2001 and Berkeley HealthLab in September 2007, broadening into adjacent life sciences and clinical laboratory capabilities.

Celera Genomics was acquired by Applied Biosystems in 2011, ending its independent operations. Source data also references a separate or successor entity branded "CeleraBio" that in March 2025 entered a strategic partnership with Shiseido to co-develop gene-targeted eye-area skincare ingredients, indicating continued use of the Celera brand in adjacent biotech applications. The firmographic data shows internal inconsistencies — the short description ("Genotyping for Infectious diseases") and 501-1000 employee count conflict with the 2011 acquisition and documented human genome focus, suggesting data conflation between the original Celera Genomics and a successor or related entity.

Short descriptiontext

Celera (Celera Genomics), founded in 1998 by J. Craig Venter, pioneered whole-genome shotgun sequencing and assembled the first human genome draft in 2000. The company was acquired by Applied Biosystems in 2011; a related entity, CeleraBio, remains active in skincare biotech.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersAlameda, United States
HQ citystring
Alameda
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
genomic sequencing services, DNA sequencing, human genome analysis, biomedical research, genomic data generation
Industry3 codes
PRIMARYHLAAANAA
Genomic Profiling & Sequencing-Based Precision Medicine
SECONDARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
Product category
Genomic Sequencing Services
Social media profiles1 record
Cost components4 values
Personnel, Technology or R&D, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Celera Genomics provided DNA sequencing services and genomic data generation for biomedical research, employing its proprietary whole-genome shotgun sequencing method to decode entire genomes faster than traditional mapping-based approaches. Its work centered on sequencing the human genome and supporting downstream scientific and synthetic biology applications for research customers.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Celera (historically known as Celera Genomics) was a genomics company founded by J. Craig Venter in 1998 to compete with the publicly funded Human Genome Project. The company pioneered whole-genome shotgun sequencing and achieved the first draft sequence of the human genome in 2000, announced alongside the Human Genome Project at the White House. Celera published its genome findings in 2001. Celera's core business centered on DNA sequencing services, genomic data generation, and synthetic biology applications. Separate from the original Celera Genomics, CeleraBio operates as a biotech firm focused on gene-targeted skincare ingredient development, notably partnering with Shiseido in March 2025 for eye-area skincare ingredients.

Product and service2 records
1Human genome sequencing services
CategoryGenomic Sequencing Services
2Genomic data generation and analysis
CategoryGenomic Data Services
Partnership1 partner
1Shiseido
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-03-01
Description

Shiseido formed a strategic partnership with biotech firm CeleraBio in March 2025 to co-develop gene-targeted eye-area skincare ingredients. This partnership focuses on leveraging genomic research for cosmetic applications.

wiseguyreports.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

One of the largest clinical laboratory services companies in the US, offering genetic, molecular, and infectious disease diagnostics to hospitals, physicians, and patients. Directly comparable to Celera as a reference laboratory serving similar end markets with overlapping test menus.

TypeDirect peer
Description

Major clinical diagnostics laboratory with substantial infectious disease and molecular testing capabilities, including genotyping services. Comparable to Celera as a full-service reference lab competing for hospital and physician testing volume.

TypeDirect peer
Description

Specialized genetic testing company offering cell-free DNA and molecular diagnostics across reproductive health, oncology, and infectious disease. Comparable to Celera as a genomics-driven diagnostics services company serving clinical customers.

TypeDirect peer
Description

Genetic testing company focused on hereditary cancer, pharmacogenomics, and other molecular diagnostics. Comparable to Celera in offering clinical-grade genomic testing services to physicians and patients through specialized lab workflows.

TypeDirect peer
Description

Precision oncology company using next-generation sequencing for liquid biopsy and tumor profiling. Comparable to Celera in operating a high-throughput clinical genomics laboratory with proprietary sequencing workflows.

TypeDirect peer
Description

Genetic information company offering medical-grade genetic testing across multiple specialties including infectious and rare diseases. Comparable to Celera as a clinical genomics services provider with a broad test menu and digital health infrastructure.

TypeEmerging player
Description

Population genomics and preventive health company offering genetic testing at scale to employers, health systems, and consumers. Comparable to Celera in translating genomic sequencing into clinical and consumer health applications.

TypeEmerging player
Description

Population genomics and clinical genetic testing platform operating a next-generation sequencing lab-as-a-service. Comparable to Celera in providing high-throughput genomic sequencing infrastructure to clinical and research customers.

TypeBroad incumbent
Description

Dominant provider of next-generation sequencing instruments, reagents, and related services globally. Comparable to Celera as an enabling technology and services provider across the genomics value chain, though operating at much larger scale as an upstream platform.

TypeBroad incumbent
Description

Global life sciences tools and diagnostics company, owner of Applied Biosystems (which acquired Celera Genomics in 2011). Comparable as a broad incumbent in genomics instruments, clinical diagnostics, and laboratory services that overlaps heavily with Celera's technology base.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Celera

Genomic Sequencing Servicescelera.com

Celera (Celera Genomics), founded in 1998 by J. Craig Venter, pioneered whole-genome shotgun sequencing and assembled the first human genome draft in 2000. The company was acquired by Applied Biosystems in 2011; a related entity, CeleraBio, remains active in skincare biotech.

What Celera does

Celera, legally known as Celera Genomics, was a private biotechnology company founded in 1998 by J. Craig Venter and headquartered in Rockville, Maryland. The company was established to compete with the publicly funded Human Genome Project by employing a whole-genome shotgun sequencing approach — a method that randomly fragments an entire genome into small pieces, sequences them in parallel, and reassembles them computationally. Celera successfully assembled the first human genome draft sequence and announced the result at the White House in 2000 alongside the NIH-led public consortium, validating the private-sector approach to large-scale genomics.

The company's core business centered on DNA sequencing services, genomic data generation, and synthetic biology applications, primarily serving research institutions and biomedical scientists who required faster, more cost-effective genome sequencing than the public mapping-based approach. Its horizontal segmentation strategy targeted scientific researchers needing genomic sequencing for their research programs. Beyond sequencing, the firm expanded through acquisitions of Axys Pharmaceuticals in June 2001 and Berkeley HealthLab in September 2007, broadening into adjacent life sciences and clinical laboratory capabilities.

Celera Genomics was acquired by Applied Biosystems in 2011, ending its independent operations. Source data also references a separate or successor entity branded "CeleraBio" that in March 2025 entered a strategic partnership with Shiseido to co-develop gene-targeted eye-area skincare ingredients, indicating continued use of the Celera brand in adjacent biotech applications. The firmographic data shows internal inconsistencies — the short description ("Genotyping for Infectious diseases") and 501-1000 employee count conflict with the 2011 acquisition and documented human genome focus, suggesting data conflation between the original Celera Genomics and a successor or related entity.

Celera firmographics

Firmographics
Name
Celera
Legal name
Celera Genomics
Website
https://celera.com
Company type
Private
Founded year
1998
Operating status
Acquired
Headcount range
501–1,000 employees
Short description
Celera (Celera Genomics), founded in 1998 by J. Craig Venter, pioneered whole-genome shotgun sequencing and assembled the first human genome draft in 2000. The company was acquired by Applied Biosystems in 2011; a related entity, CeleraBio, remains active in skincare biotech.
Ownership category
akta.pro rank

Celera industry classification

Industry
Product category
Genomic Sequencing Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)
akta.pro industry
PRIMARYHLAAANAA
Genomic Profiling & Sequencing-Based Precision Medicine
SECONDARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)

Keywords

  • Genomic sequencing services
  • DNA sequencing
  • Human genome analysis
  • Biomedical research
  • Genomic data generation

Where Celera is headquartered

Location

Headquarters

HQ city
Alameda
HQ country
United States
HQ region
North America

Markets served

Celera business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure

Celera product offering

Product offering

Core offering

Celera Genomics provided DNA sequencing services and genomic data generation for biomedical research, employing its proprietary whole-genome shotgun sequencing method to decode entire genomes faster than traditional mapping-based approaches. Its work centered on sequencing the human genome and supporting downstream scientific and synthetic biology applications for research customers.

Product overview

Celera (historically known as Celera Genomics) was a genomics company founded by J. Craig Venter in 1998 to compete with the publicly funded Human Genome Project. The company pioneered whole-genome shotgun sequencing and achieved the first draft sequence of the human genome in 2000, announced alongside the Human Genome Project at the White House. Celera published its genome findings in 2001. Celera's core business centered on DNA sequencing services, genomic data generation, and synthetic biology applications. Separate from the original Celera Genomics, CeleraBio operates as a biotech firm focused on gene-targeted skincare ingredient development, notably partnering with Shiseido in March 2025 for eye-area skincare ingredients.

Differentiator

Problem solved

Functional benefit

Products and services

  • Human genome sequencing services
  • Genomic data generation and analysis

Companies that use Celera

Customer profile

Segments1 record

Ideal customer profiles1 record

Celera technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Celera partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • ShiseidominorStrategic or Co-development Partner · 1 March 2025Shiseido formed a strategic partnership with biotech firm CeleraBio in March 2025 to co-develop gene-targeted eye-area skincare ingredients. This partnership focuses on leveraging genomic research for cosmetic applications.

Recent moves5 records

Expansion highlights1 record

Celera competitors and assessment

Company assessment

Direct peers

  • Quest Diagnostics: One of the largest clinical laboratory services companies in the US, offering genetic, molecular, and infectious disease diagnostics to hospitals, physicians, and patients. Directly comparable to Celera as a reference laboratory serving similar end markets with overlapping test menus.
  • Labcorp: Major clinical diagnostics laboratory with substantial infectious disease and molecular testing capabilities, including genotyping services. Comparable to Celera as a full-service reference lab competing for hospital and physician testing volume.
  • Natera: Specialized genetic testing company offering cell-free DNA and molecular diagnostics across reproductive health, oncology, and infectious disease. Comparable to Celera as a genomics-driven diagnostics services company serving clinical customers.
  • Myriad Genetics: Genetic testing company focused on hereditary cancer, pharmacogenomics, and other molecular diagnostics. Comparable to Celera in offering clinical-grade genomic testing services to physicians and patients through specialized lab workflows.
  • Guardant Health: Precision oncology company using next-generation sequencing for liquid biopsy and tumor profiling. Comparable to Celera in operating a high-throughput clinical genomics laboratory with proprietary sequencing workflows.
  • Invitae: Genetic information company offering medical-grade genetic testing across multiple specialties including infectious and rare diseases. Comparable to Celera as a clinical genomics services provider with a broad test menu and digital health infrastructure.

Emerging players

  • Color Health: Population genomics and preventive health company offering genetic testing at scale to employers, health systems, and consumers. Comparable to Celera in translating genomic sequencing into clinical and consumer health applications.
  • Helix: Population genomics and clinical genetic testing platform operating a next-generation sequencing lab-as-a-service. Comparable to Celera in providing high-throughput genomic sequencing infrastructure to clinical and research customers.

Broad incumbents

  • Illumina: Dominant provider of next-generation sequencing instruments, reagents, and related services globally. Comparable to Celera as an enabling technology and services provider across the genomics value chain, though operating at much larger scale as an upstream platform.
  • Thermo Fisher Scientific: Global life sciences tools and diagnostics company, owner of Applied Biosystems (which acquired Celera Genomics in 2011). Comparable as a broad incumbent in genomics instruments, clinical diagnostics, and laboratory services that overlaps heavily with Celera's technology base.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights5 records

Customer concentration

Celera social profiles

Digital presence

Celera financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Celera leadership team

Management profile

Number of profiles

Celera funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Celera M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celera

What does Celera do?

Celera Genomics provided DNA sequencing services and genomic data generation for biomedical research, employing its proprietary whole-genome shotgun sequencing method to decode entire genomes faster than traditional mapping-based approaches. Its work centered on sequencing the human genome and supporting downstream scientific and synthetic biology applications for research customers.

Is Celera a public or private company?

Celera is a private company. It is classified as corporate owned and is currently acquired.

When was Celera founded?

Celera was founded in 1998. It employs 501 to 1,000 people.

Where is Celera based?

Celera is headquartered in Alameda, United States, in the North America region.

Who are Celera's main competitors?

Direct peers on record are Quest Diagnostics, Labcorp, Natera, Myriad Genetics, Guardant Health and Invitae. Emerging players are Color Health and Helix. Broad incumbents are Illumina and Thermo Fisher Scientific.

Does Celera have an API?

No public API is recorded for Celera.

What industry is Celera in?

Celera's product category is Genomic Sequencing Services. Its primary akta.pro industry code is HLAAANAA, Genomic Profiling & Sequencing-Based Precision Medicine, with a secondary code of HLAGANAA, Genomics & Next-Generation Sequencing (NGS) Services. Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NatureJ. Craig Venter obituary: maverick biotechnologist who sequenced the human genomeJ. Craig Venter, the maverick biotechnologist who co-sequenced the human genome and pioneered synthetic biology, died on May 6, 2026 at age 79, after a career marked by fierce competition with the publicly funded Human Genome Project. His companies Celera Genomics and the Institute for Genomic Research challenged the international consortium, culminating in the 2000 White House announcement of the first human genome draft, alongside milestones including the first bacterial genome (1995), first individual human genome (2007), and first synthetic cell (2010). While celebrated as an innovative scientist who demonstrated entrepreneurship's power in research, he was controversial for attempts to patent gene fragments and was dubbed "Darth Venter" by critics.ChosunbizGenomics Pioneer John Craig Venter Dies at 79Genomics pioneer John Craig Venter died at age 79 on the 29th of last month due to complications from cancer treatment, the Craig Venter Institute announced. Venter led the private-sector effort to sequence the human genome through Celera Genomics, competing alongside the publicly-funded Human Genome Project, and declared the completion of the draft human genome at the White House in 2000. Beyond genome sequencing, Venter advanced into synthetic biology by creating the world's first synthetic organism 'Synthia' in 2010 and later developed a minimal synthetic cell capable of self-replication.YahooJ. Craig Venter, pioneer of human genome sequencing, dies at 79J. Craig Venter, the pioneering geneticist who produced the first draft of the human genome in 2000 and advanced understanding of how genes influence human life, died Wednesday at age 79 in San Diego. Venter's private company Celera Genomics competed with the government-run Human Genome Project to decode the 3.1 billion sub-units of DNA, and both announced the breakthrough together in 2000. His death was announced by the J. Craig Venter Institute, where he served as founder and where he was hospitalized for side effects from recent cancer treatment.citybizJ. Craig Venter, Pioneering Genome Scientist and Entrepreneur, Dies at 79J. Craig Venter, the pioneering genome scientist who helped decode the human genome and transformed modern biology, died Wednesday in San Diego at age 79 from complications related to cancer treatment. Venter challenged the federally funded Human Genome Project in the 1990s with his faster whole-genome shotgun sequencing approach, and in 2000 his company Celera Genomics announced alongside a public consortium the successful assembly of the first human genome sequence, a milestone that revolutionized biomedical science. Earlier, in 1995, Venter and his team sequenced the genome of Haemophilus influenzae, the first free-living organism to have its full genetic code decoded.HpcwireSince 1987 – Covering the Fastest Computers in the World and the People Who Run ThemJ. Craig Venter, the pioneering scientist who led the team that first sequenced the human genome, died April 29 near his home in La Jolla, California. Venter developed the "whole-genome shotgun" technique using supercomputers and machine learning to map entire genomes, and founded Celera Genomics in 1998 to compete with the NIH-led Human Genome Project before both teams jointly announced the first draft sequence at the White House in 2000. Following his genome work, Venter went on to co-found Synthetic Genomics, establish the J. Craig Venter Institute, and launch Human Longevity, Inc. to study applications of genetic data, leaving a legacy of risk-taking innovation that reshaped genomics.UsnewsJ. Craig Venter, Who Won the Race to Sequence the Human Genome, Dies at 79J. Craig Venter, the biologist who mapped the first draft of the human genome and competed with the government-led Human Genome Project, died at age 79 in San Diego after being hospitalized for side effects from cancer treatment. In 2000, Venter's private company Celera Genomics, alongside Human Genome Project leaders, announced they had decoded the 3.1 billion sub-units of DNA that make up human life. His work helped scientists understand genetic causes for diseases and he was the first to publish his own sequenced genome, opening doors to personalized treatments.Chemical & Engineering NewsJ. Craig Venter, foil of the Human Genome Project, dies at 79J. Craig Venter, a biologist and entrepreneur who helped shape modern genomics, died on April 29, 2026, at age 79 following unexpected side effects from cancer treatment, according to an announcement from the J. Craig Venter Institute. Venter founded Celera Genomics in 1998 to race the international Human Genome Project, successfully sequencing the human genome using his whole-genome shotgun approach and publishing it alongside the HGP in 2001, fundamentally accelerating the field. His career also included pioneering the first complete bacterial genome sequence, claiming creation of synthetic life, publishing his own genome as the first individual to do so, and leading the Global Ocean Sampling Expedition, with accolades including the National Medal of Science in 2008.NatureGenome pioneer Craig Venter dies: here’s how he transformed scienceCraig Venter, the maverick scientist who led the commercial effort to sequence the human genome, died on April 29 at age 79, leaving behind a legacy that transformed genomics and synthetic biology. His career included co-founding the Institute for Genomics Research (TIGR) in 1992, establishing Celera Genomics in 1998 to compete with the publicly funded Human Genome Project, and pioneering the whole genome shotgun sequencing method still used today. Venter later founded the J. Craig Venter Institute in 2006, where he led work creating the first organisms with synthetic genomes, which he characterised as the first synthetic life.WiseGuy ReportsEye Skin Care Market Size, Trends & Forecast 2035The global eye skin care market is projected to grow from USD 4.26 billion in 2024 to USD 6.75 billion by 2035, reflecting a compound annual growth rate of approximately 4.3% during the forecast period. Key industry developments include Shiseido's March 2025 strategic partnership with biotech firm CeleraBio to co-develop gene-targeted eye-area skincare ingredients, Beiersdorf's June 2024 acquisition of a premium eye-care line for North American market expansion, and Estée Lauder Companies' February 2025 launch of a Bakuchiol-based eye serum targeting fine lines and puffiness. Growth drivers include rising consumer awareness of eye care, an aging global population, increasing demand for anti-aging products, and the growing popularity of natural and organic ingredients, with North America currently commanding the largest market share while Asia-Pacific emerges as the fastest-growing region.YahooThis Zeppelin-Shaped Business Jet Offers Longer Range and Better Fuel EfficiencyOtto Aviation's Celera 500L is a six-seat business jet with 18-25 mpg fuel economy, a 4,500-nm range, and $328-per-hour operating costs. Its push-propeller design and laminar-flow wings cut drag by up to 60% and enable cross-continental US flights without refueling.